Safety profile of prophylactic rescue dosing of immediate-release oral opioids in cancer patients
Tóm tắt
Appropriate prophylactic rescue dosing of opioids is considered effective for cancer pain relief, but no study has reported the safety of such prophylactic rescue. We compared the safety of prophylactic rescue dosing of immediate-release oral opioids with that of regular rescue dosing. The study included 103 cancer patients who used either immediate-release morphine syrup or immediate-release oxycodone powder at Shizuoka Cancer Center between January and December 2016. Patients were divided into those who mostly used (prophylactic group) and those who never used (regular group) prophylactic rescue doses of opioids and compared the incidence of adverse events (AEs). We also investigated whether the prophylactic rescue dose negatively interfered with its objective activity, such as meals. Incidence of each AE in the prophylactic versus regular groups was as follows: somnolence, 20.6% versus 14.3%; nausea, 22.1% versus 17.1%; constipation, 19.1% versus 20.0%; urinary retention, 1.5% versus 2.9%; delirium, 4.4% versus 8.6%; and pruritus, 0% versus 2.9%. No serious AE associated with prophylactic rescue dosing was observed. No significant difference was observed in the incidence of any AE between the two groups (p > 0.05, Fisher’s exact test). No AE interfered with the objective activity of the prophylactic rescue dose. Incidence of AEs associated with prophylactic rescue dosing is not different from that associated with regular rescue dosing. In addition, the prophylactic rescue dose did not adversely affect its objective activity, suggesting the safety of appropriate prophylactic rescue dosing was similar to that of regular rescue dosing. The study approval number in the institution;
H29-J30–29–1-3
. Registered June 5, 2017.
Tài liệu tham khảo
World Health Organization. WHO Cancer Pain Relief. 1st ed. Geneva, Switzerland: World Health Organization; 1986.
World Health Organization. WHO Cancer Pain Relief: With a Guide to Opioid Availability. Geneva, Switzerland: World Health Organization; 1996.
Mercadante S. Opioid titration in cancer pain: a clinical review. Eur J Pain. 2007;11:823–30.
Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manag. 1993;8:63–7.
Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van HI, et al. Efficacy and safety of tapentadol extended release compared with oxycodone-controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized double-blind, placebo- and active-controlled phase 3 study. Clin Drug Investig. 2010;30:489–505.
Canada H. Fentanyl transdermal patch and fatal adverse reactions. Can Adverse Reac Newslet. 2008;18(3):1–2.
Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic neuropathic pain. A long-term, open-label safety study. Cancer. 2009;115:2571–9.
Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–85.
Kleptstad P, Kaasa S, Borchgrevink PC. Starting step 3 opioids for moderate to severe pain in cancer patients: dose titration: a systematic review. Palliat Med. 2011;25:424–30.
Davis MP, Walsh D, Lagman R, Legrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005;6:696–704.
Davis MP. Guidelines for breakthrough pain dosing. Am J Hosp Palliat Care. 2003;20:334.
Opso® comprehensive drug information sheet. Tokyo: Dainihon Sumitomo Co., Ltd; 2014.
Oxinorm® comprehensive drug information sheet. Tokyo: Shionogi Co., Ltd; 2014.
Couzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSR). Pain. 2001;91:123–30.
Magnani C, Giannarelli D, Casale G. Procedural pain in palliative care: is it breakthrough pain? A multicenter National Prospective Study to assess prevalence, intensity, and treatment of procedure-related pain in patients with advanced disease. Clin J Pain. 2017;33:707–14.
Augusto C, Geoffrey H, Stein K, Bannett MI, Brunelli C, Chemy N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.
Japanese society for palliative medicine. Clinical guidelines for cancer pain management. 2nd ed. Tokyo: Kanehara Co.; 2014.
Gagnon B, Bilelech M, Watanabe S, Walker P, Hanson J, Bruera E. The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer. 1999;7:265–70.
Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–15.
National Comprehensive Cancer Network (Version 2): NCCN Clinical Practice Guidelines in Oncology. Adult cancer pain; 2016. https://oralcancerfoundation.org/wp-content/uploads/2016/09/pain.pdf.
Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, Mcquay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.
Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manag. 2009;38:418–25.
Nakamura A, Hasegawa M, Ito H, Minami K, Koike K, Habu N, et al. Distinct relations among plasma concentration required for different pharmacological effects in oxycodone, morphine, and fentanyl. J Pain Palliat Care Pharmacother. 2011;4:318–34.
Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18:17–30.
Mazzocate C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilator function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol. 1999;10:1511–4.